Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease or Motor Neurone Disease (MND), is a fatal neurodegenerative disorder with life expectancy of less than 5 years after diagnosis in most cases. The urgent need for diagnosis and treatment has seen an enormous increase of studies searching for objective Biomarkers in recent years. This excellent review by Kirk SE et al., (2019) discusses ALS biomarkers, and among these, urinary NGFR/p75ECD has emerged as an important marker with both prognostic and disease progression value.
ELISA assays are widely utilized to measure Biomarkers in human fluids, but poorly validated immunoassays will produce inaccurate data and thus lead to incorrect conclusions. Biosensis has released a new, improved version of its leading Human NGFR/p75ECD RapidTM ELISA kit (BEK-2239), specifically formulated and validated for excellent accuracy and reproducibility in human urine.
The Art of Obtaining Accurate ELISA Data – Why Parallelism Matters!
When it comes to immunoassay development, optimizing the interaction of assay antibodies, reference standard, natural target and sample matrix is crucial for data accuracy. Dilutional linearity of endogenous target (also known as Parallelism) establishes the compatibility of the assay antibodies with the matrix, and the suitability of the reference standard representing the natural target.
Figure and Table: p75ECD concentrations in six normal human urine samples. Excellent parallelism to the reference cure and thus accurate quantification is demonstrated graphically (left), and in the table with inter-dilution CV of less than 13.9% (right). See our kit insert for a full summary of accuracy and precision data for our Human NGFR/p75ECD RapidTM ELISA Kit (BEK-2239).
Interested to read more about ELISA assay validation? See our Technical Note for further information. Want to know more about our improved Human NGFR/p75ECD RapidTM ELISA kit (BEK-2239)? Contact us at email@example.com.